Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KLH + peptides + dendritic cells
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intradermal, Subcutaneous, Intravenous, Intranodal
01
Overview
KLH + peptides + dendritic cells is an investigational therapeutic cancer vaccine composed of autologous or donor-derived dendritic cells (DCs) that are ex vivo loaded (pulsed) with tumor-associated antigenic peptides and the carrier protein keyhole limpet hemocyanin (KLH). The combination is designed to induce a robust antigen-specific immune response by leveraging the potent antigen-presenting capacity of DCs. Peptides derived from tumor antigens are presented to T-cells to elicit cytotoxic responses against cancer cells, while co-loading with KLH serves as an immunogenic control and adjuvant, enhancing CD4+ T-cell priming and facilitating monitoring of immune responses. This approach has been studied in various cancers including melanoma, acute myeloid leukemia, and colorectal cancer[1][2][3][5]. The mechanism involves both cellular (T-cell mediated) and humoral (antibody-mediated) immunity.
- Other names
- KLH-loaded peptide-pulsed dendritic cell vaccineDC vaccine with KLH and peptidespeptide-pulsed DCs with KLH
02
Targets
HLA-B7MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on KLH + peptides + dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KLH + peptides + dendritic cells.